Loading…
Control of cancer stem cell like population by intracellular target identification followed by the treatment with peptide-siRNA complex
Cancer stem cells (CSCs) are a subpopulation of cancer cells and have been known to create cancer reoccurrence during cancer therapy due to their stem cell-like characteristics. However, exact target to control the CSC has not been fully established. Here, we enriched CD44High population of MDA-MB-2...
Saved in:
Published in: | Biochemical and biophysical research communications 2017-09, Vol.491 (3), p.827-833 |
---|---|
Main Authors: | , , , , , , , , , |
Format: | Article |
Language: | English |
Subjects: | |
Citations: | Items that this one cites Items that cite this one |
Online Access: | Get full text |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
cited_by | cdi_FETCH-LOGICAL-c356t-4d1dd715529289f8c1d6e95317c49876643021a9a469b2e245c85cfa3f5018013 |
---|---|
cites | cdi_FETCH-LOGICAL-c356t-4d1dd715529289f8c1d6e95317c49876643021a9a469b2e245c85cfa3f5018013 |
container_end_page | 833 |
container_issue | 3 |
container_start_page | 827 |
container_title | Biochemical and biophysical research communications |
container_volume | 491 |
creator | Suh, Jin Sook Lee, Hyun Jung Nam, Hyun Jo, Beom Soo Lee, Dong Woo Kim, Ji-Hye Lee, Jue Yeon Chung, Chong Pyoung Lee, Gene Park, Yoon Jeong |
description | Cancer stem cells (CSCs) are a subpopulation of cancer cells and have been known to create cancer reoccurrence during cancer therapy due to their stem cell-like characteristics. However, exact target to control the CSC has not been fully established. Here, we enriched CD44High population of MDA-MB-231 cells by CD44 antibody as a CSC marker. By Phospho Antibody Array, CD44High population of MDA-MB-231 cells reveals Feline sarcoma-related tyrosine kinase (FER) protein was highly activated. When FER siRNA and low molecular weight protamine (LMWP) as cell penetrating peptides are applied to this population, cancer migration and colony forming ability are inhibited. Moreover, silencing FER using FER siRNA and LMWP conjugates enhances anti-metastasis related factors including E-cadherin, p75 and p63. Taken together, FER is a new marker for targeting breast CSCs and peptide-mediated siRNA method could be an effective and safe way of delivery and be a new therapeutic strategy for targeting breast cancer.
•FER protein is highly activated in the cancer stem cells derived from human breast tumors.•Silencing FER by siRNA reduces stemness and metastatic features of cancer stem cells.•FER siRNA complex with the cell-penetrating peptide showed more effective and less toxic method. |
doi_str_mv | 10.1016/j.bbrc.2017.05.148 |
format | article |
fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_1903943740</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0006291X17310483</els_id><sourcerecordid>1903943740</sourcerecordid><originalsourceid>FETCH-LOGICAL-c356t-4d1dd715529289f8c1d6e95317c49876643021a9a469b2e245c85cfa3f5018013</originalsourceid><addsrcrecordid>eNp9kUFv1DAQhS0EotvCH-CAfOSSMHbsJJa4VKtCkSqQEEjcLMeZUC9OHGwvpb-Av42jLRw5jTTzvSe9eYS8YFAzYO3rQz0M0dYcWFeDrJnoH5EdAwUVZyAekx0AtBVX7OsZOU_pAMCYaNVTcsZ7KUUvxI783oclx-BpmKg1i8VIU8aZWvSeevcd6RrWozfZhYUO99QV2mzHsos0m_gNM3UjLtlNzp6wKXgf7nDc-HyLNEc0eS4IvXP5lq645qKokvv04ZLaMK8efz0jTybjEz5_mBfky9urz_vr6ubju_f7y5vKNrLNlRjZOHZMSq54r6besrFFJRvWWaH6rm1FA5wZZUrOgSMX0vbSTqaZJLAeWHNBXp181xh-HDFlPbu05TELhmPSTEGjRNMJKCg_oTaGlCJOeo1uNvFeM9BbAfqgtwL0VoAGqUsBRfTywf84zDj-k_z9eAHenAAsKX86jDpZh-Xxo4tosx6D-5__HxeDmKg</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1903943740</pqid></control><display><type>article</type><title>Control of cancer stem cell like population by intracellular target identification followed by the treatment with peptide-siRNA complex</title><source>ScienceDirect Freedom Collection 2022-2024</source><creator>Suh, Jin Sook ; Lee, Hyun Jung ; Nam, Hyun ; Jo, Beom Soo ; Lee, Dong Woo ; Kim, Ji-Hye ; Lee, Jue Yeon ; Chung, Chong Pyoung ; Lee, Gene ; Park, Yoon Jeong</creator><creatorcontrib>Suh, Jin Sook ; Lee, Hyun Jung ; Nam, Hyun ; Jo, Beom Soo ; Lee, Dong Woo ; Kim, Ji-Hye ; Lee, Jue Yeon ; Chung, Chong Pyoung ; Lee, Gene ; Park, Yoon Jeong</creatorcontrib><description>Cancer stem cells (CSCs) are a subpopulation of cancer cells and have been known to create cancer reoccurrence during cancer therapy due to their stem cell-like characteristics. However, exact target to control the CSC has not been fully established. Here, we enriched CD44High population of MDA-MB-231 cells by CD44 antibody as a CSC marker. By Phospho Antibody Array, CD44High population of MDA-MB-231 cells reveals Feline sarcoma-related tyrosine kinase (FER) protein was highly activated. When FER siRNA and low molecular weight protamine (LMWP) as cell penetrating peptides are applied to this population, cancer migration and colony forming ability are inhibited. Moreover, silencing FER using FER siRNA and LMWP conjugates enhances anti-metastasis related factors including E-cadherin, p75 and p63. Taken together, FER is a new marker for targeting breast CSCs and peptide-mediated siRNA method could be an effective and safe way of delivery and be a new therapeutic strategy for targeting breast cancer.
•FER protein is highly activated in the cancer stem cells derived from human breast tumors.•Silencing FER by siRNA reduces stemness and metastatic features of cancer stem cells.•FER siRNA complex with the cell-penetrating peptide showed more effective and less toxic method.</description><identifier>ISSN: 0006-291X</identifier><identifier>EISSN: 1090-2104</identifier><identifier>DOI: 10.1016/j.bbrc.2017.05.148</identifier><identifier>PMID: 28554844</identifier><language>eng</language><publisher>United States: Elsevier Inc</publisher><subject>Apoptosis - drug effects ; Apoptosis - genetics ; Cell Line, Tumor ; Cell penetrating peptide ; Epithelial-to-mesenchymal transition ; FER siRNA delivery ; FER tyrosine kinase ; Gene Silencing ; Gene Targeting - methods ; Genetic Therapy - methods ; Human breast cancer stem cells ; Humans ; Molecular Targeted Therapy - methods ; Neoplastic Stem Cells - drug effects ; Neoplastic Stem Cells - physiology ; Peptides - administration & dosage ; Peptides - pharmacokinetics ; Pluripotency ; Protein-Tyrosine Kinases - antagonists & inhibitors ; Protein-Tyrosine Kinases - genetics ; RNA, Small Interfering - genetics ; RNA, Small Interfering - therapeutic use ; Treatment Outcome</subject><ispartof>Biochemical and biophysical research communications, 2017-09, Vol.491 (3), p.827-833</ispartof><rights>2017</rights><rights>Copyright © 2017. Published by Elsevier Inc.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c356t-4d1dd715529289f8c1d6e95317c49876643021a9a469b2e245c85cfa3f5018013</citedby><cites>FETCH-LOGICAL-c356t-4d1dd715529289f8c1d6e95317c49876643021a9a469b2e245c85cfa3f5018013</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27924,27925</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/28554844$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Suh, Jin Sook</creatorcontrib><creatorcontrib>Lee, Hyun Jung</creatorcontrib><creatorcontrib>Nam, Hyun</creatorcontrib><creatorcontrib>Jo, Beom Soo</creatorcontrib><creatorcontrib>Lee, Dong Woo</creatorcontrib><creatorcontrib>Kim, Ji-Hye</creatorcontrib><creatorcontrib>Lee, Jue Yeon</creatorcontrib><creatorcontrib>Chung, Chong Pyoung</creatorcontrib><creatorcontrib>Lee, Gene</creatorcontrib><creatorcontrib>Park, Yoon Jeong</creatorcontrib><title>Control of cancer stem cell like population by intracellular target identification followed by the treatment with peptide-siRNA complex</title><title>Biochemical and biophysical research communications</title><addtitle>Biochem Biophys Res Commun</addtitle><description>Cancer stem cells (CSCs) are a subpopulation of cancer cells and have been known to create cancer reoccurrence during cancer therapy due to their stem cell-like characteristics. However, exact target to control the CSC has not been fully established. Here, we enriched CD44High population of MDA-MB-231 cells by CD44 antibody as a CSC marker. By Phospho Antibody Array, CD44High population of MDA-MB-231 cells reveals Feline sarcoma-related tyrosine kinase (FER) protein was highly activated. When FER siRNA and low molecular weight protamine (LMWP) as cell penetrating peptides are applied to this population, cancer migration and colony forming ability are inhibited. Moreover, silencing FER using FER siRNA and LMWP conjugates enhances anti-metastasis related factors including E-cadherin, p75 and p63. Taken together, FER is a new marker for targeting breast CSCs and peptide-mediated siRNA method could be an effective and safe way of delivery and be a new therapeutic strategy for targeting breast cancer.
•FER protein is highly activated in the cancer stem cells derived from human breast tumors.•Silencing FER by siRNA reduces stemness and metastatic features of cancer stem cells.•FER siRNA complex with the cell-penetrating peptide showed more effective and less toxic method.</description><subject>Apoptosis - drug effects</subject><subject>Apoptosis - genetics</subject><subject>Cell Line, Tumor</subject><subject>Cell penetrating peptide</subject><subject>Epithelial-to-mesenchymal transition</subject><subject>FER siRNA delivery</subject><subject>FER tyrosine kinase</subject><subject>Gene Silencing</subject><subject>Gene Targeting - methods</subject><subject>Genetic Therapy - methods</subject><subject>Human breast cancer stem cells</subject><subject>Humans</subject><subject>Molecular Targeted Therapy - methods</subject><subject>Neoplastic Stem Cells - drug effects</subject><subject>Neoplastic Stem Cells - physiology</subject><subject>Peptides - administration & dosage</subject><subject>Peptides - pharmacokinetics</subject><subject>Pluripotency</subject><subject>Protein-Tyrosine Kinases - antagonists & inhibitors</subject><subject>Protein-Tyrosine Kinases - genetics</subject><subject>RNA, Small Interfering - genetics</subject><subject>RNA, Small Interfering - therapeutic use</subject><subject>Treatment Outcome</subject><issn>0006-291X</issn><issn>1090-2104</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2017</creationdate><recordtype>article</recordtype><recordid>eNp9kUFv1DAQhS0EotvCH-CAfOSSMHbsJJa4VKtCkSqQEEjcLMeZUC9OHGwvpb-Av42jLRw5jTTzvSe9eYS8YFAzYO3rQz0M0dYcWFeDrJnoH5EdAwUVZyAekx0AtBVX7OsZOU_pAMCYaNVTcsZ7KUUvxI783oclx-BpmKg1i8VIU8aZWvSeevcd6RrWozfZhYUO99QV2mzHsos0m_gNM3UjLtlNzp6wKXgf7nDc-HyLNEc0eS4IvXP5lq645qKokvv04ZLaMK8efz0jTybjEz5_mBfky9urz_vr6ubju_f7y5vKNrLNlRjZOHZMSq54r6besrFFJRvWWaH6rm1FA5wZZUrOgSMX0vbSTqaZJLAeWHNBXp181xh-HDFlPbu05TELhmPSTEGjRNMJKCg_oTaGlCJOeo1uNvFeM9BbAfqgtwL0VoAGqUsBRfTywf84zDj-k_z9eAHenAAsKX86jDpZh-Xxo4tosx6D-5__HxeDmKg</recordid><startdate>20170923</startdate><enddate>20170923</enddate><creator>Suh, Jin Sook</creator><creator>Lee, Hyun Jung</creator><creator>Nam, Hyun</creator><creator>Jo, Beom Soo</creator><creator>Lee, Dong Woo</creator><creator>Kim, Ji-Hye</creator><creator>Lee, Jue Yeon</creator><creator>Chung, Chong Pyoung</creator><creator>Lee, Gene</creator><creator>Park, Yoon Jeong</creator><general>Elsevier Inc</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>20170923</creationdate><title>Control of cancer stem cell like population by intracellular target identification followed by the treatment with peptide-siRNA complex</title><author>Suh, Jin Sook ; Lee, Hyun Jung ; Nam, Hyun ; Jo, Beom Soo ; Lee, Dong Woo ; Kim, Ji-Hye ; Lee, Jue Yeon ; Chung, Chong Pyoung ; Lee, Gene ; Park, Yoon Jeong</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c356t-4d1dd715529289f8c1d6e95317c49876643021a9a469b2e245c85cfa3f5018013</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2017</creationdate><topic>Apoptosis - drug effects</topic><topic>Apoptosis - genetics</topic><topic>Cell Line, Tumor</topic><topic>Cell penetrating peptide</topic><topic>Epithelial-to-mesenchymal transition</topic><topic>FER siRNA delivery</topic><topic>FER tyrosine kinase</topic><topic>Gene Silencing</topic><topic>Gene Targeting - methods</topic><topic>Genetic Therapy - methods</topic><topic>Human breast cancer stem cells</topic><topic>Humans</topic><topic>Molecular Targeted Therapy - methods</topic><topic>Neoplastic Stem Cells - drug effects</topic><topic>Neoplastic Stem Cells - physiology</topic><topic>Peptides - administration & dosage</topic><topic>Peptides - pharmacokinetics</topic><topic>Pluripotency</topic><topic>Protein-Tyrosine Kinases - antagonists & inhibitors</topic><topic>Protein-Tyrosine Kinases - genetics</topic><topic>RNA, Small Interfering - genetics</topic><topic>RNA, Small Interfering - therapeutic use</topic><topic>Treatment Outcome</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Suh, Jin Sook</creatorcontrib><creatorcontrib>Lee, Hyun Jung</creatorcontrib><creatorcontrib>Nam, Hyun</creatorcontrib><creatorcontrib>Jo, Beom Soo</creatorcontrib><creatorcontrib>Lee, Dong Woo</creatorcontrib><creatorcontrib>Kim, Ji-Hye</creatorcontrib><creatorcontrib>Lee, Jue Yeon</creatorcontrib><creatorcontrib>Chung, Chong Pyoung</creatorcontrib><creatorcontrib>Lee, Gene</creatorcontrib><creatorcontrib>Park, Yoon Jeong</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Biochemical and biophysical research communications</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Suh, Jin Sook</au><au>Lee, Hyun Jung</au><au>Nam, Hyun</au><au>Jo, Beom Soo</au><au>Lee, Dong Woo</au><au>Kim, Ji-Hye</au><au>Lee, Jue Yeon</au><au>Chung, Chong Pyoung</au><au>Lee, Gene</au><au>Park, Yoon Jeong</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Control of cancer stem cell like population by intracellular target identification followed by the treatment with peptide-siRNA complex</atitle><jtitle>Biochemical and biophysical research communications</jtitle><addtitle>Biochem Biophys Res Commun</addtitle><date>2017-09-23</date><risdate>2017</risdate><volume>491</volume><issue>3</issue><spage>827</spage><epage>833</epage><pages>827-833</pages><issn>0006-291X</issn><eissn>1090-2104</eissn><abstract>Cancer stem cells (CSCs) are a subpopulation of cancer cells and have been known to create cancer reoccurrence during cancer therapy due to their stem cell-like characteristics. However, exact target to control the CSC has not been fully established. Here, we enriched CD44High population of MDA-MB-231 cells by CD44 antibody as a CSC marker. By Phospho Antibody Array, CD44High population of MDA-MB-231 cells reveals Feline sarcoma-related tyrosine kinase (FER) protein was highly activated. When FER siRNA and low molecular weight protamine (LMWP) as cell penetrating peptides are applied to this population, cancer migration and colony forming ability are inhibited. Moreover, silencing FER using FER siRNA and LMWP conjugates enhances anti-metastasis related factors including E-cadherin, p75 and p63. Taken together, FER is a new marker for targeting breast CSCs and peptide-mediated siRNA method could be an effective and safe way of delivery and be a new therapeutic strategy for targeting breast cancer.
•FER protein is highly activated in the cancer stem cells derived from human breast tumors.•Silencing FER by siRNA reduces stemness and metastatic features of cancer stem cells.•FER siRNA complex with the cell-penetrating peptide showed more effective and less toxic method.</abstract><cop>United States</cop><pub>Elsevier Inc</pub><pmid>28554844</pmid><doi>10.1016/j.bbrc.2017.05.148</doi><tpages>7</tpages></addata></record> |
fulltext | fulltext |
identifier | ISSN: 0006-291X |
ispartof | Biochemical and biophysical research communications, 2017-09, Vol.491 (3), p.827-833 |
issn | 0006-291X 1090-2104 |
language | eng |
recordid | cdi_proquest_miscellaneous_1903943740 |
source | ScienceDirect Freedom Collection 2022-2024 |
subjects | Apoptosis - drug effects Apoptosis - genetics Cell Line, Tumor Cell penetrating peptide Epithelial-to-mesenchymal transition FER siRNA delivery FER tyrosine kinase Gene Silencing Gene Targeting - methods Genetic Therapy - methods Human breast cancer stem cells Humans Molecular Targeted Therapy - methods Neoplastic Stem Cells - drug effects Neoplastic Stem Cells - physiology Peptides - administration & dosage Peptides - pharmacokinetics Pluripotency Protein-Tyrosine Kinases - antagonists & inhibitors Protein-Tyrosine Kinases - genetics RNA, Small Interfering - genetics RNA, Small Interfering - therapeutic use Treatment Outcome |
title | Control of cancer stem cell like population by intracellular target identification followed by the treatment with peptide-siRNA complex |
url | http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-01T03%3A51%3A19IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Control%20of%20cancer%20stem%20cell%20like%20population%20by%20intracellular%20target%20identification%20followed%20by%20the%20treatment%20with%20peptide-siRNA%20complex&rft.jtitle=Biochemical%20and%20biophysical%20research%20communications&rft.au=Suh,%20Jin%20Sook&rft.date=2017-09-23&rft.volume=491&rft.issue=3&rft.spage=827&rft.epage=833&rft.pages=827-833&rft.issn=0006-291X&rft.eissn=1090-2104&rft_id=info:doi/10.1016/j.bbrc.2017.05.148&rft_dat=%3Cproquest_cross%3E1903943740%3C/proquest_cross%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c356t-4d1dd715529289f8c1d6e95317c49876643021a9a469b2e245c85cfa3f5018013%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=1903943740&rft_id=info:pmid/28554844&rfr_iscdi=true |